Laboratorios Farmaceuticos Rovi has secured FDA approval for Risvan, or risperidone for extended-release injectable suspension, to treat adult patients with schizophrenia. The decision was based on the findings of a Phase 3 study, in which the drug led to improvements in Positive and Negative Syndrome Scale total scores.